The classical models of progesterone action held that the biological activities of progestins and antiprogestins are mediated through a specific high-affinity receptor protein located in the nuclei of target cells. According to this model, upon agonist binding the progesterone receptor (PR) is converted into a transcriptionally-active form and antagonists manifest their activity by competitively blocking agonist access to the receptor. This relatively simple model has become more complex with the discovery that this receptor can exist in either of two functionally-distinct forms within target cells: hPR-A and hPR-B. The additional finding that the classical role of a ligand as a molecular switch, converting PR from an inactive to an active form, does not adequately describe the pharmacology of the known PR-ligands. In the last funding period, we focused on these two aspects of PR-action and determined that the A and B forms of this receptor have distinct, opposing roles. Specifically, it was found that hPR-B is an activator of progesterone-responsive genes in most cells, whereas hPR-A is a ligand-dependent inhibitor of hPR-B function. It was demonstrated also that agonist- or antagonist-activated hPR-A can modulate the ability of cells to respond to estrogens, androgens, glucocorticoids and mineralocorticoids, suggesting that hPR-A is a key point of convergence between these signaling systems. The pharmacology of PR was compounded further upon the observation that different ligands have different effects on PR-structure, and that cells possess machinery to distinguish between these structurally- distinct complexes. Dissection of the molecular basis for this selectivity has enabled us to identify a novel class of selective progesterone receptor modulators (SPRMs) which function as agonists in some environments and antagonists in others. We propose, therefore, in the upcoming funding period, to focus on defining the mechanisms underlying the differential transcriptional activity of hPR-A and hPR-B and the means by which the activities of these receptors are influenced by ligands. Reflecting these overall objectives and taking into consideration our preliminary data, we propose the following specific aims:(1) Identification and characterization of peptides which interact with agonist or antagonist activated hPR-A or hPR- B. (2) Development and use of peptide antagonists of hPR-A and hPR-B to identify isoform-specific biological activities. (3) Definition of the molecular mechanism of action of the selective progesterone receptor modulators (SPRMs). (4) Identification of cellular factors which modulate PR-pharmacology.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK050494-08
Application #
6517375
Study Section
Endocrinology Study Section (END)
Program Officer
Margolis, Ronald N
Project Start
1995-05-01
Project End
2005-04-30
Budget Start
2002-05-01
Budget End
2003-04-30
Support Year
8
Fiscal Year
2002
Total Cost
$283,762
Indirect Cost
Name
Duke University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
071723621
City
Durham
State
NC
Country
United States
Zip Code
27705
Chang, Ching-yi; Norris, John D; Jansen, Michelle et al. (2003) Application of random peptide phage display to the study of nuclear hormone receptors. Methods Enzymol 364:118-42
Sathya, Ganesan; Chang, Ching-yi; Kazmin, Dmitri et al. (2003) Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion. Cancer Res 63:8029-36
Li, Xiaolin; McDonnell, Donald P (2002) The transcription factor B-Myb is maintained in an inhibited state in target cells through its interaction with the nuclear corepressors N-CoR and SMRT. Mol Cell Biol 22:3663-73
Li, Xiaolin; Kimbrel, Erin A; Kenan, Daniel J et al. (2002) Direct interactions between corepressors and coactivators permit the integration of nuclear receptor-mediated repression and activation. Mol Endocrinol 16:1482-91
Chang, C Y; Walther, P J; McDonnell, D P (2001) Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer. Cancer Res 61:8712-7
Ito, A; Lai, C H; Zhao, X et al. (2001) p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J 20:1331-40
Hamilton, M H; Tcherepanova, I; Huibregtse, J M et al. (2001) Nuclear import/export of hRPF1/Nedd4 regulates the ubiquitin-dependent degradation of its nuclear substrates. J Biol Chem 276:26324-31
Wagner, B L; Pollio, G; Giangrande, P et al. (1999) The novel progesterone receptor antagonists RTI 3021-012 and RTI 3021-022 exhibit complex glucocorticoid receptor antagonist activities: implications for the development of dissociated antiprogestins. Endocrinology 140:1449-58
Wagner, B L; Norris, J D; Knotts, T A et al. (1998) The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol Cell Biol 18:1369-78
Imhof, M O; McDonnell, D P (1996) Yeast RSP5 and its human homolog hRPF1 potentiate hormone-dependent activation of transcription by human progesterone and glucocorticoid receptors. Mol Cell Biol 16:2594-605

Showing the most recent 10 out of 11 publications